Firefly Neuroscience (NASDAQ:AIFF) Stock Rating Upgraded by Wall Street Zen

Firefly Neuroscience (NASDAQ:AIFF) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Firefly Neuroscience in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Firefly Neuroscience Stock Performance

AIFF stock opened at $1.76 on Friday. The company has a market capitalization of $26.03 million, a PE ratio of -0.98 and a beta of 0.58. Firefly Neuroscience has a one year low of $0.62 and a one year high of $4.51. The company’s 50 day moving average price is $1.52 and its two-hundred day moving average price is $1.56.

Firefly Neuroscience (NASDAQ:AIFF) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($0.16) EPS for the quarter. The business had revenue of $0.41 million for the quarter. Firefly Neuroscience had a negative return on equity of 229.99% and a negative net margin of 1,740.98%.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in AIFF. Jane Street Group LLC purchased a new position in shares of Firefly Neuroscience in the fourth quarter worth $53,000. Savvy Advisors Inc. purchased a new position in Firefly Neuroscience during the 3rd quarter valued at $63,000. Geode Capital Management LLC increased its position in Firefly Neuroscience by 92.9% during the 2nd quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock valued at $341,000 after purchasing an additional 58,067 shares during the period. Finally, Vanguard Group Inc. increased its position in Firefly Neuroscience by 393.3% during the 3rd quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock valued at $1,464,000 after purchasing an additional 401,085 shares during the period. 4.96% of the stock is owned by hedge funds and other institutional investors.

Firefly Neuroscience Company Profile

Firefly Neuroscience is a clinical?stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real?world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone?based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.